康希诺生物发布年度业绩股东应占亏损14.83亿元同比扩大63.04%

智通财经03-27

康希诺生物(06185)发布截至2023年12月31日止的年度业绩，该集团期内取得收入3.45亿元(人民币，下同)，同比减少66.52%;股东应占亏损14.83亿元，同比扩大63.04%;每股基本亏损6.01元。公告称，收益减少主要因COVID-19疫苗产品需求减少及计提COVID-19疫苗产品退货约2.53亿元(2022年：约2.90亿元)，对收入产生负面影响。报告期内集团的流脑疫苗产品收入约为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2422910945?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-03-27 23:38","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2422910945","market":"sh","top_or_hot":-1,"title":"康希诺生物发布年度业绩 股东应占亏损14.83亿元 同比扩大63.04%","media":"智通财经","content":"<div>\n<p>康希诺生物(06185)发布截至2023年12月31日止的年度业绩，该集团期内取得收入3.45亿元(人民币，下同)，同比减少66.52%;股东应占亏损14.83亿元，同比扩大63.04%;每股基本亏损6.01元。公告称，收益减少主要因COVID-19疫苗产品需求减少及计提COVID-19疫苗产品退货约2.53亿元(2022年：约2.90亿元)，对收入产生负面影响。报告期内集团的流脑疫苗产品收入约为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272355348b6a388b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康希诺生物发布年度业绩 股东应占亏损14.83亿元 同比扩大63.04%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康希诺生物发布年度业绩 股东应占亏损14.83亿元 同比扩大63.04%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-27 23:38 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272355348b6a388b&s=b><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>康希诺生物(06185)发布截至2023年12月31日止的年度业绩，该集团期内取得收入3.45亿元(人民币，下同)，同比减少66.52%;股东应占亏损14.83亿元，同比扩大63.04%;每股基本亏损6.01元。公告称，收益减少主要因COVID-19疫苗产品需求减少及计提COVID-19疫苗产品退货约2.53亿元(2022年：约2.90亿元)，对收入产生负面影响。报告期内集团的流脑疫苗产品收入约为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272355348b6a388b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272355348b6a388b&s=b","article_id":"2422910945","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272355348b6a388b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2422910945","pubTimestamp":1711553900,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"康希诺生物发布截至2023年12月31日止的年度业绩，该集团期内取得收入3.45亿元，同比减少66.52%;股东应占亏损14.83亿元，同比扩大63.04%;每股基本亏损6.01元。公告称，收益减少主要因COVID-19疫苗产品需求减少及计提COVID-19疫苗产品退货约2.53亿元，对收入产生负面影响。研发开支由截至2022年12月31日止年度的约7.78亿元减少18.0%至截至2023年12月31日止年度的约6.38亿元，主要由于COVID-19疫苗产品的临床试验及测试费减少导致疫苗研发临床试验及测试费减少约2.49亿元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688185":"康希诺","BK0239":"医药制造"},"translate_title":"CanSino Biologics released annual results. The loss attributable to shareholders was 1.483 billion yuan, an increase of 63.04% year-on-year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688185":0.9},"content_text":"康希诺生物(06185)发布截至2023年12月31日止的年度业绩，该集团期内取得收入3.45亿元(人民币，下同)，同比减少66.52%;股东应占亏损14.83亿元，同比扩大63.04%;每股基本亏损6.01元。公告称，收益减少主要因COVID-19疫苗产品需求减少及计提COVID-19疫苗产品退货约2.53亿元(2022年：约2.90亿元)，对收入产生负面影响。报告期内集团的流脑疫苗产品收入约为5.62亿元(2022年：约1.53亿元)。该增长主要是由于流脑疫苗持续商业化所致。研发开支由截至2022年12月31日止年度的约7.78亿元减少18.0%至截至2023年12月31日止年度的约6.38亿元，主要由于COVID-19疫苗产品的临床试验及测试费减少导致疫苗研发临床试验及测试费减少约2.49亿元。该减少被雇员福利开支增加约7920万元;及折旧及摊销费用增加约2270万元所部分抵销。该等增加主要是由于COVID-19疫苗以外的多种在研疫苗的研发取得进展，尤其是接近商业化阶段的在研疫苗。集团的疫苗产品线在战略上旨在针对庞大且供不应求的全球市场，可总结为3个类别：全球创新疫苗(如集团的克威莎、克威莎雾优、Ad5-EBOV、在研mRNA新冠疫苗、在研结核病加强疫苗、在研PBPV、在研重组带状疱疹疫苗及在研破伤风疫苗)，以迎合全球尚未满足的医疗需求;所开发具有更高质量以取代中国现时主流疫苗的中国首创疫苗(如集团的曼海欣及美奈喜，在研PCV13i、青少年及成人用Tdcp疫苗、婴幼儿用DTcP以及重组脊髓灰质炎疫苗);及临床前候选疫苗(如集团的Hib疫苗、CS-2023脑膜炎疫苗、CS-2028多价肺炎结合疫苗及CS-2201组分百白破联合疫苗)。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422910945"}

康希诺生物发布年度业绩 股东应占亏损14.83亿元 同比扩大63.04%

精彩评论

康希诺生物发布年度业绩股东应占亏损14.83亿元同比扩大63.04%